Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Recombinant Interleukin-12 in Advanced Solid Tumors
NCT03030378Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2018
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant interleukin-12 in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose up to 5 years and Recommended Phase 2 Dose up to 5 years. Started May 2018; status: active, not recruiting.
02
Drugs
recombinant interleukin-12
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03030378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030378.